These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32198151)

  • 1. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
    Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
    Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
    Roeker LE; Mato AR
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
    Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirtobrutinib
    Al-Sawaf O; Jen MH; Hess LM; Zhang J; Goebel B; Pagel JM; Abhyankar S; Davids MS; Eyre TA
    Haematologica; 2024 Jun; 109(6):1866-1873. PubMed ID: 38031799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
    Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
    Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
    Shadman M; Manzoor BS; Sail K; Tuncer HH; Allan JN; Ujjani C; Emechebe N; Kamalakar R; Coombs CC; Leslie L; Barr PM; Brown JR; Eyre TA; Rampotas A; Schuh A; Lamanna N; Skarbnik A; Roeker LE; Bannerji R; Eichhorst B; Fleury I; Davids MS; Alhasani H; Jiang D; Hill BT; Schuster SJ; Brander DM; Pivneva I; Burne R; Guerin A; Mato AR
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):515-526. PubMed ID: 37076367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Ghosh N; Manzoor BS; Fakhri B; Emechebe N; Alhasani H; Skarbnik A; Jawaid D; Shadman M
    Br J Haematol; 2024 Oct; 205(4):1395-1403. PubMed ID: 39049159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review.
    Zuber M; Akkala S; Li N; Veettil SK; Tan CJ; Villa Zapata L
    Cancer Med; 2024 Sep; 13(18):e70258. PubMed ID: 39344587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
    Yin Y; Athanasiadis P; Karlsen L; Urban A; Xu H; Murali I; Fernandes SM; Arribas AJ; Hilli AK; Taskén K; Bertoni F; Mato AR; Normant E; Brown JR; Tjønnfjord GE; Aittokallio T; Skånland SS
    Clin Cancer Res; 2022 Oct; 28(20):4444-4455. PubMed ID: 35998013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Roeker LE; Woyach JA; Cheah CY; Coombs CC; Shah NN; Wierda WG; Patel MR; Lamanna N; Tsai DE; Nair B; Wang C; Zhao X; Liu D; Radtke D; Chapman S; Marella N; McNeely SC; Brown JR
    Blood; 2024 Sep; 144(13):1374-1386. PubMed ID: 38861666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Huntington SF; Manzoor BS; Puckett JT; Kamal-Bahl S; Alhasani H; Ravelo A; Jawaid D; Doshi JA
    Leuk Lymphoma; 2023 Dec; 64(14):2316-2323. PubMed ID: 37732602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for anti-CD20 antibodies in CLL?
    Shah HR; Stephens DM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
    Rogers KA
    Clin Cancer Res; 2020 Jul; 26(14):3501-3502. PubMed ID: 32366672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.